Premium
Clinical uses of metal‐binding drugs
Author(s) -
Chenoweth Maynard B.
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196893365
Subject(s) - dimercaprol , metal poisoning , penicillamine , mercury (programming language) , cadmium , beryllium , pharmacology , chelation therapy , medicine , chemistry , mercury poisoning , chelation , toxicity , heavy metals , environmental chemistry , inorganic chemistry , organic chemistry , computer science , programming language
To summarize the current position of metal‐chelating drugs in medicine is not difficult. Arsenic and mercury poisonings call for immediate systematic treatment with dimercaprol; symptoms of chronic lead poisoning respond well to systemic calcium disodium edetate; Wilson's disease is ameliorated by oral D‐penicillamine and all the other situations discussed are still experimental and sub iudice. Many of the observations reported on the effects of these drugs do not seem to be clearly related to metal binding. Certain toxic metals such as cadmium, thallium, beryllium, and manganese have, as yet, no notably effective antidotes.